Perbandingan Luaran Klinis Favipiravir dan Remdesivir pada Pasien Covid-19 Derajat Sedang di RS Akademik UGM Yogyakarta
Research on effective antivirals for COVID-19 is still ongoing. Favipiravir and remdesivir are antivirals that have been recommended in Indonesia. This study aimed to compare the clinical outcomes of favipiravir and remdesivir in moderate COVID-19 patients. This research is a retrospective cohort st...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Indonesian |
| Published: |
Universitas Gadjah Mada
2023-09-01
|
| Series: | Jurnal Manajemen dan Pelayanan Farmasi |
| Subjects: | |
| Online Access: | https://jurnal.ugm.ac.id/jmpf/article/view/84815 |
| _version_ | 1797322297121439744 |
|---|---|
| author | Hadiatussalamah Hadiatussalamah Tri Murti Andayani Ika Puspita Sari |
| author_facet | Hadiatussalamah Hadiatussalamah Tri Murti Andayani Ika Puspita Sari |
| author_sort | Hadiatussalamah Hadiatussalamah |
| collection | DOAJ |
| description | Research on effective antivirals for COVID-19 is still ongoing. Favipiravir and remdesivir are antivirals that have been recommended in Indonesia. This study aimed to compare the clinical outcomes of favipiravir and remdesivir in moderate COVID-19 patients. This research is a retrospective cohort study conducted at the UGM Academic Hospital Yogyakarta using electronic medical records of moderate COVID-19 who were hospitalized from June 2021 to March 2022. Each therapy group consisted of 88 subjects. Clinical outcomes in the form of improved and not-improved conditions were assessed using a 7-point ordinal scale of progressivity and recovery of COVID-19 from WHO. Chi-square analysis and multiple logistic regression were performed to determine the relationship between the research variables. The highest percentage of research subjects were aged 18 – 59 years (70,5%), male (53,4%), and not obese (64,2%). The most common comorbidities were diabetes mellitus (33%) and hypertension (30%). The favipiravir group had a better clinical outcome than remdesivir. The proportion of patients improving in the favipiravir group was 50,0% and 35,3% in the remdesivir group (p-value=0,048). There was no significant difference in the number of adverse events between both study groups (p-value > 0,05). The most common adverse drug events were nausea (35,2%), vomiting (14,2%), and heartburn (11,4%). |
| first_indexed | 2024-03-08T05:11:13Z |
| format | Article |
| id | doaj.art-796a917cc21047d4a24b304442a93583 |
| institution | Directory Open Access Journal |
| issn | 2088-8139 2443-2946 |
| language | Indonesian |
| last_indexed | 2024-03-08T05:11:13Z |
| publishDate | 2023-09-01 |
| publisher | Universitas Gadjah Mada |
| record_format | Article |
| series | Jurnal Manajemen dan Pelayanan Farmasi |
| spelling | doaj.art-796a917cc21047d4a24b304442a935832024-02-07T09:10:09ZindUniversitas Gadjah MadaJurnal Manajemen dan Pelayanan Farmasi2088-81392443-29462023-09-0113310.22146/jmpf.8481534594Perbandingan Luaran Klinis Favipiravir dan Remdesivir pada Pasien Covid-19 Derajat Sedang di RS Akademik UGM YogyakartaHadiatussalamah Hadiatussalamah0Tri Murti Andayani1Ika Puspita Sari2Magister Farmasi Klinik, Fakultas Farmasi, Universitas Gadjah MadaDepartemen Farmakologi dan Farmasi Klinik, Fakultas Farmasi, Universitas Gadjah MadaDepartemen Farmakologi dan Farmasi Klinik, Fakultas Farmasi, Universitas Gadjah MadaResearch on effective antivirals for COVID-19 is still ongoing. Favipiravir and remdesivir are antivirals that have been recommended in Indonesia. This study aimed to compare the clinical outcomes of favipiravir and remdesivir in moderate COVID-19 patients. This research is a retrospective cohort study conducted at the UGM Academic Hospital Yogyakarta using electronic medical records of moderate COVID-19 who were hospitalized from June 2021 to March 2022. Each therapy group consisted of 88 subjects. Clinical outcomes in the form of improved and not-improved conditions were assessed using a 7-point ordinal scale of progressivity and recovery of COVID-19 from WHO. Chi-square analysis and multiple logistic regression were performed to determine the relationship between the research variables. The highest percentage of research subjects were aged 18 – 59 years (70,5%), male (53,4%), and not obese (64,2%). The most common comorbidities were diabetes mellitus (33%) and hypertension (30%). The favipiravir group had a better clinical outcome than remdesivir. The proportion of patients improving in the favipiravir group was 50,0% and 35,3% in the remdesivir group (p-value=0,048). There was no significant difference in the number of adverse events between both study groups (p-value > 0,05). The most common adverse drug events were nausea (35,2%), vomiting (14,2%), and heartburn (11,4%).https://jurnal.ugm.ac.id/jmpf/article/view/84815covid-19antiviralluaran klinisfavipiravirremdesivir |
| spellingShingle | Hadiatussalamah Hadiatussalamah Tri Murti Andayani Ika Puspita Sari Perbandingan Luaran Klinis Favipiravir dan Remdesivir pada Pasien Covid-19 Derajat Sedang di RS Akademik UGM Yogyakarta Jurnal Manajemen dan Pelayanan Farmasi covid-19 antiviral luaran klinis favipiravir remdesivir |
| title | Perbandingan Luaran Klinis Favipiravir dan Remdesivir pada Pasien Covid-19 Derajat Sedang di RS Akademik UGM Yogyakarta |
| title_full | Perbandingan Luaran Klinis Favipiravir dan Remdesivir pada Pasien Covid-19 Derajat Sedang di RS Akademik UGM Yogyakarta |
| title_fullStr | Perbandingan Luaran Klinis Favipiravir dan Remdesivir pada Pasien Covid-19 Derajat Sedang di RS Akademik UGM Yogyakarta |
| title_full_unstemmed | Perbandingan Luaran Klinis Favipiravir dan Remdesivir pada Pasien Covid-19 Derajat Sedang di RS Akademik UGM Yogyakarta |
| title_short | Perbandingan Luaran Klinis Favipiravir dan Remdesivir pada Pasien Covid-19 Derajat Sedang di RS Akademik UGM Yogyakarta |
| title_sort | perbandingan luaran klinis favipiravir dan remdesivir pada pasien covid 19 derajat sedang di rs akademik ugm yogyakarta |
| topic | covid-19 antiviral luaran klinis favipiravir remdesivir |
| url | https://jurnal.ugm.ac.id/jmpf/article/view/84815 |
| work_keys_str_mv | AT hadiatussalamahhadiatussalamah perbandinganluaranklinisfavipiravirdanremdesivirpadapasiencovid19derajatsedangdirsakademikugmyogyakarta AT trimurtiandayani perbandinganluaranklinisfavipiravirdanremdesivirpadapasiencovid19derajatsedangdirsakademikugmyogyakarta AT ikapuspitasari perbandinganluaranklinisfavipiravirdanremdesivirpadapasiencovid19derajatsedangdirsakademikugmyogyakarta |